UK 100 equity research

Explore the most viewed and latest equity research and media content for the top 100 largest listed companies in the UK.


UK 100 Equity Research

Broker research, valuations, & analysis on the UK 100

Latest Content

Hikma Pharmaceuticals

Mediocre H2 amid muted FY 19 guidance

Hikma’s H2 18 top-line missed our as well as the street’s expectations marginally. Revenue was up by 4.4% to $1.09bn, driven by the robust performance by the Generic segment (+14%). A decline in the Branded segment (-1%; FX headwinds played a major role), was compensated by a marginal increase in the Injectables (+1%). On the profitability front, the EBITDA margin was up by 5.6ppt to 27%, attributable to a reduction in COGS (47.8% of sales vs 50.3% in H2 17; due to the consolidation of the manufacturing facilities), S&M (6.9% of sales vs 10% in H2 17) and G&A (8.8% of sales vs 10.7% in H2 17), partially offset by an increase in R&D (7.7% of sales vs 5.6% in H2 17). All FY 18 sales numbers are at CER unless specified otherwise. Revenue was up by 8% to $2.07bn, driven by strong across the business segments – Injectables (+6%), Branded (+5%) and Generic (+13%). The core operating margin was up by 2.3ppt to 22.2%, benefiting from the closing down of the Eatontown plant and the integration of the Memphis distribution into the Columbus facility – largely pertaining to the generic business (core operating margin of 13.4% vs 3.6% in FY17), supported by a minor increase in the Branded margin (21.6% vs 21.3% in FY 17), partially offset by a marginal decline in the Injectables margin (40.3% vs 40.6% in FY 17). We expect the manufacturing efficiencies to help realise savings of $20-30m annually from 2019, implying a higher operating margin in the Generics business in the coming years (management targets mid-teens vs 13.4% in 2018). FX had a negative impact of 1ppt on sales. Geographically, the US (62% of total revenue) grew by 8% to $1.3bn, benefiting from the opioid drug-shortage and the strong uptake of new generic drugs, partially offset by a decline in the legacy injectables portfolio and the ongoing pricing pressure in the generic industry. MENA (32% of total revenue) was up by 4.1% to $656m, supported by the strong uptake of the Remsima (biosimilar) in the Injectables segment (+21%), and the solid performance of the Branded segment in Egypt, mitigated by a weak performance in Saudi Arabia and Algeria along with the FX headwinds of 4%. Europe and ROW (6% of total revenue) was up by 15% to $121m, driven by the recent launch of lyophilised products. Our concern was the weak guidance for FY19 — Injectables (revenue $850-900m; core operating margin of 35-38%), Generics (revenue $650-700m; core operating margin in mid-teens), and Branded (revenue growth in mid single-digit), implying group revenue in the range of $2.07-2.17bn.

  • 15 Mar 19
  • -
  • -